Last reviewed · How we verify
mistletoe
At a glance
| Generic name | mistletoe |
|---|---|
| Sponsor | National Center for Complementary and Integrative Health (NCCIH) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma (PHASE2)
- Therapeutic Instillation of Mistletoe (PHASE3)
- Viscum Album for TNBC on Adjuvant Pembrolizumab (PHASE4)
- Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors (PHASE4)
- Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer (PHASE3)
- Trial of Mistletoe Extract in Patients With Advanced Solid Tumors (PHASE1)
- Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
- A Prospective Dose Finding Study of Iscador Infusion (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mistletoe CI brief — competitive landscape report
- mistletoe updates RSS · CI watch RSS
- National Center for Complementary and Integrative Health (NCCIH) portfolio CI